

**Melanoma Research Alliance Scientific Retreat
February 24-26, 2009
Washington, DC**

Tuesday, February 24, 2009

- 4:00 pm **Registration Desk Opens – Diplomat Ballroom Foyer**
- 7:00 pm **Welcome Reception - Diplomat Ballroom**
- 8:00 pm **Registration Ends**

All activities in Blue Room unless noted

Wednesday, February 25, 2009

- 7:00 – 11:00 am **Registration Desk Opens**
- 7:00 – 8:00 am **Breakfast**
- 8:00 – 8:10 am **Overview and Introductions** Alison Martin, M.D.
- Welcome Remarks:** Leon and Debra Black

**Session I: Latest Trends in Epidemiology, Prevention, Risk Assessment
8:10 --10:00 am Co-Leaders: Drs. Halpern and Mann**

- 8:10 – 8:20 am **Introduction**
Allan Halpern, M.D.
Memorial Sloan-Kettering Cancer Center
- 8:20 – 8:30 am **Risk Stratification**
Peggy Tucker, M.D.
National Cancer Institute
Discussion: 10 min
- 8:40 – 8:50 am **Primary Prevention**
Julia Newton-Bishop, M.D.
University of Leeds
Discussion: 10 min

9:00 – 9:10 am **Early Detection**
Martin Weinstock, M.D., Ph.D.
Brown University
Discussion: 10 min

9:20 – 9:30 am **Genetics toward Prevention**
Graham Mann, Ph.D., FRACP
University of Sydney
Discussion: 10 min

9:40 – 9:55 am **Panel Discussion**

Session II: Genomics and Target Validation: Prospects for the Future

10:00-11:45 am Co-leaders: Drs. Bastian and Garraway

10:00 – 10:10 am **Applications of “Next Generation” Genomic Technologies for Melanoma Target Validation**
Levi A. Garraway, M.D., Ph.D.
Dana-Farber Cancer Center
Discussion: 10 min

10:20 – 10:30 am **The Role of Genome Characterization in Melanoma Disease Stratification**
Boris Bastian, M.D.
University of California – San Francisco
Discussion: 10 min

10:40 – 10:50 am **Functional RET Gene Polymorphism in Cutaneous Melanoma**
David Hoon, M.Sc., Ph.D.
John Wayne Cancer Institute
Discussion: 10 min

11:00 – 11:10 am **From Target Validation to Drug Discovery in Melanoma: The Academic-Industry Interface**
Nathanael Gray, Ph.D.
Dana-Farber Cancer Institute
Discussion: 10 min

11:20 – 11:45 am **Panel Discussion**

12:00-1:00 pm Lunch – Diplomat Ballroom
Speaker: Mike Milken, *FasterCures* Chairman and MRA Board Member

Session III: Drug Discovery and Development
1:15 -- 3:00 pm Co-leaders: Drs. Weber and Fisher

- 1:15 – 1:25 pm **B-Raf and its Drugs**
Richard Marais, M.D.
Insitute of Cancer Research, London
Discussion: 10 min
- 1:35 – 1:45 pm **Impact of Genomic Complexity on Ras/B-Raf Addiction**
David Solit, M.D.
Memorial Sloan-Kettering Cancer Center
Discussion: 10 min
- 1:55 – 2:05 pm **Stat Signaling as a Target in Melanoma**
Hua Yu, Ph.D.
City of Hope
Discussion: 10 min
- 2:15 – 2:25 pm **Targeting MITF for Melanoma Treatment and Prevention**
David Fisher, M.D., Ph.D.
MGH/Harvard
Discussion: 10 min
- 2:35 – 2:55 pm **Panel Discussion**

Session IV: Checkpoint Blockade

3:00 – 5:00 pm **Co-leaders: Drs. Allison and Dranoff**

- 3:00 – 3:10 pm **New Strategy of Checkpoint Blockade: Introduction and Overview**
Jim Allison, M.D.
Memorial Sloan-Kettering Cancer Center
Discussion: 10 min
- 3:20 – 3:30 pm **Clinical Experience with CTLA-4 Blockade in Melanoma**
Jedd Wolchok, M.D., Ph.D.
Memorial Sloan-Kettering Cancer Center
Discussion: 10 min
- 3:40 – 3:50 pm **Biomarkers of Effectiveness in Melanoma**
Padmanee Sharma, M.D., Ph.D.
M.D. Anderson Cancer Center
Discussion: 10 min
- 4:00 – 4:10 pm **Experience to Date with PD-1 Blockade: Next in Line**
Suzanne Topalian, M.D.
Johns Hopkins University
Discussion: 10 min
- 4:20 – 4:30 pm **Future Direction: MFG-E8 Blockade**
Glenn Dranoff, M.D.
Dana-Farber Cancer Institute
Discussion: 10 min

4:40 – 4:55 pm

Panel Discussion

5:00 – 6:00 pm

Special Lecture: Immune Modulation and Molecular Targeting in Melanoma - Separate but Equal?

Moderator: Suzanne Topalian, M.D.
Johns Hopkins University

Speakers: Mike Weber, Ph.D.
University of Virginia Cancer Center
Discussion: 10 min

Dr. Steve Rosenberg, M.D., Ph.D.
National Cancer Institute
Discussion: 10 min

7:00 pm

Dinner

**New Heights Restaurant, 2317 Calvert Street, NW
(one block from Omni)**

**Speaker: Sam Donaldson, ABC News Correspondent
& Melanoma survivor**

Thursday, February 26, 2009

7:30 – 8:30 am

Breakfast

Session V: Melanoma Stem Cells - Fact or Fiction

8:30 – 9:55 am Moderator: Meenhard Herlyn, Ph.D.
Wistar Institute

8:40 – 8:55 am Speakers: Mark Shackleton, M.D., Ph.D.
University of Michigan
Discussion: 10 minutes

9:05 – 9:20 am Jonathan Cebon, MBBS, FRACP, Ph.D.
Ludwig Institute for Cancer Research
Discussion: 10 minutes

9:30 – 9:55 am

Panel Discussion

**Session VI: Maximizing Drug Development – Global Landscape,
Cotargeting Prospects, Multisector Partnerships**

10:00 – 11:45 am Moderator: Greg Simon
President, *FasterCures*

Discussants: Jeffrey Abrams, M.D.
Associate Director, Cancer Therapy Evaluation Program,
National Cancer Institute

Jonathan Cebon, MBBS, FRACP, Ph.D.
Ludwig Institute for Cancer Research

Keith Flaherty, M.D.
University of Pennsylvania

Jonathan Simons, M.D.
Prostate Cancer Foundation

Special Invited Guests from industry, NCI, and FDA

11:45 – 12:00 pm

Closing Remarks

Alison Martin, M.D.

12:00 pm

Lunch (available for carryout)